PROCUREMENT PLAN (Textual Part)

Project information: Egypt Transforming Egypt's Healthcare System Project P167000

Project Implementation agency: Ministry of Health and Population

Date of the Procurement Plan: October 23, 2018

Period covered by this Procurement Plan: 18 months

Preamble

In accordance with paragraph 5.9 of the “World Bank Procurement Regulations for IPF Borrowers” (July 2016) (“Procurement Regulations”) the Bank’s Systematic Tracking and Exchanges in Procurement (STEP) system will be used to prepare, clear and update Procurement Plans and conduct all procurement transactions for the Project.

This textual part along with the Procurement Plan tables in STEP constitute the Procurement Plan for the Project. The following conditions apply to all procurement activities in the Procurement Plan. The other elements of the Procurement Plan as required under paragraph 4.4 of the Procurement Regulations are set forth in STEP.

The Bank’s Standard Procurement Documents: shall be used for all contracts subject to international competitive procurement and those contracts as specified in the Procurement Plan tables in STEP.

National Procurement Arrangements: In accordance with paragraph 5.3 of the Procurement Regulations, when approaching the national market (as specified in the Procurement Plan tables in STEP), the country’s own procurement procedures may be used.

Leased Assets: “Not Applicable”

Procurement of Second Hand Goods: “Not Applicable”

Domestic preference as specified under paragraph 5.51 of the Procurement Regulations (Goods and Works).

Goods: is applicable for those contracts identified in the Procurement Plan tables;

Other Relevant Procurement Information.

NA
<table>
<thead>
<tr>
<th>ID</th>
<th>Name</th>
<th>ID</th>
<th>Name</th>
<th>ID</th>
<th>Name</th>
<th>ID</th>
<th>Name</th>
<th>ID</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>baroud</td>
<td>2</td>
<td>mahmoudia</td>
<td>3</td>
<td>El</td>
<td>4</td>
<td>baroud</td>
<td>5</td>
<td>mahmoudia</td>
</tr>
<tr>
<td>6</td>
<td>etay</td>
<td>7</td>
<td>el</td>
<td>8</td>
<td>baroud</td>
<td>9</td>
<td>mahmoudia</td>
<td>10</td>
<td>El</td>
</tr>
<tr>
<td>11</td>
<td>etay</td>
<td>12</td>
<td>el</td>
<td>13</td>
<td>baroud</td>
<td>14</td>
<td>mahmoudia</td>
<td>15</td>
<td>El</td>
</tr>
<tr>
<td>16</td>
<td>etay</td>
<td>17</td>
<td>el</td>
<td>18</td>
<td>baroud</td>
<td>19</td>
<td>mahmoudia</td>
<td>20</td>
<td>El</td>
</tr>
<tr>
<td>21</td>
<td>etay</td>
<td>22</td>
<td>el</td>
<td>23</td>
<td>baroud</td>
<td>24</td>
<td>mahmoudia</td>
<td>25</td>
<td>El</td>
</tr>
<tr>
<td>26</td>
<td>etay</td>
<td>27</td>
<td>el</td>
<td>28</td>
<td>baroud</td>
<td>29</td>
<td>mahmoudia</td>
<td>30</td>
<td>El</td>
</tr>
</tbody>
</table>

**Activity**: Purchasing

**Period**: 2018-10-28 to 2019-01-05

**Contract**: Signed

**Procurement**: IBRD/P167000

**Object**: Strengthening Health Care System in Post-Conflict Setting

**Population**: Revised Level 88950

**Project**: Prepared Health Care Program

**Country**: Arab Republic of Egypt

**Loan**: IBRD/88950

**Approach**: One Stage Process

**Prequalification**: Prequalification Report

**Amount**: 96,750.70

**Estimated**: 97,900.00

**Signed**: 98,363.09

**Actual**: 98,310.13

**Amount**: 97,900.00

**Estimated**: 97,900.00

**Signed**: 97,190.56

**Actual**: 97,140.56

**Minutes**: 2018-10-28

**Minutes**: 2018-11-06

**Minutes**: 2019-01-05

**Invitation**: Planned

**Prequalification**: Planned

**Documents**: Prequalification Report

**Status**: Actual

**Process**: Planned

**Prequalification**: Actual

**Notice**: Planned

**Invitation**: Issued
Sofosbuvir to Daclatasvir

Purchasing the combination currently used for the virus.

3abour

400mg+60mg

IBRD

97,700.00

98,200.00

98,363.09

97,972.25

98,363.09

97,581.41

97,581.41

2018-10-28

2018-11-06

2019-01-05

2018-10-28

2018-11-06

2019-01-05

2018-10-28

2018-11-06

2019-01-05

2018-10-28

2018-11-06

2019-01-05

2018-10-28

2018-11-06

2019-01-05

2018-10-28

2018-11-06

2019-01-05

2018-10-28

2018-11-06

2019-01-05

2018-10-28

2018-11-06

2019-01-05

2018-10-28

2018-11-06

2019-01-05

2018-10-28

2018-11-06

2019-01-05

2018-10-28

2018-11-06

2019-01-05

2018-10-28

2018-11-06

2019-01-05

2018-10-28

2018-11-06

2019-01-05

2018-10-28

2018-11-06

2019-01-05

2018-10-28

2018-11-06

2019-01-05

2018-10-28

2018-11-06

2019-01-05

2018-10-28

2018-11-06

2019-01-05
<table>
<thead>
<tr>
<th>Country Code</th>
<th>Loan Number</th>
<th>Group</th>
<th>Name of Borrower</th>
<th>Type of Loan</th>
<th>Amount (US$)</th>
<th>Interest Rate</th>
<th>Maturity Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>CC1</td>
<td>88950-1</td>
<td>A</td>
<td>ABC Corporation</td>
<td>IBRD</td>
<td>99,000</td>
<td>4.5%</td>
<td>2018-12-31</td>
</tr>
<tr>
<td>CC2</td>
<td>88950-2</td>
<td>B</td>
<td>XYZ Inc.</td>
<td>IBRD</td>
<td>98,500</td>
<td>5.0%</td>
<td>2019-01-01</td>
</tr>
<tr>
<td>CC3</td>
<td>88950-3</td>
<td>C</td>
<td>DEF LLC</td>
<td>IBRD</td>
<td>98,200</td>
<td>5.5%</td>
<td>2019-02-28</td>
</tr>
<tr>
<td>CC4</td>
<td>88950-4</td>
<td>D</td>
<td>GHI Corp.</td>
<td>IBRD</td>
<td>98,700</td>
<td>6.0%</td>
<td>2019-03-31</td>
</tr>
<tr>
<td>CC5</td>
<td>88950-5</td>
<td>E</td>
<td>JKL Inc.</td>
<td>IBRD</td>
<td>98,900</td>
<td>6.5%</td>
<td>2019-04-30</td>
</tr>
<tr>
<td>CC6</td>
<td>88950-6</td>
<td>F</td>
<td>MNO LLC</td>
<td>IBRD</td>
<td>98,850</td>
<td>7.0%</td>
<td>2019-05-31</td>
</tr>
<tr>
<td>CC7</td>
<td>88950-7</td>
<td>G</td>
<td>PQR Corp.</td>
<td>IBRD</td>
<td>97,800</td>
<td>7.5%</td>
<td>2019-06-30</td>
</tr>
<tr>
<td>CC8</td>
<td>88950-8</td>
<td>H</td>
<td>STU Inc.</td>
<td>IBRD</td>
<td>98,000</td>
<td>8.0%</td>
<td>2019-07-31</td>
</tr>
<tr>
<td>Date</td>
<td>Stage</td>
<td>Quotations Requested</td>
<td>Quotations Received</td>
<td>Signed Quotations</td>
<td>Closing Date</td>
<td>Contract Approval Date</td>
<td>Contract Implementation Date</td>
</tr>
<tr>
<td>------------</td>
<td>--------</td>
<td>-----------------------</td>
<td>---------------------</td>
<td>-------------------</td>
<td>--------------</td>
<td>------------------------</td>
<td>-----------------------------</td>
</tr>
</tbody>
</table>

**Notes:**
- The table represents the procurement process for medicines used in the treatment of Hepatitis C in the district Helwan through the programme funded by the IBRD.
- The medicines are a combination of Sofosbuvir and Daclatasvir, used in the treatment of Hepatitis C at different stages.
- The contract approval and implementation dates are provided for each stage.
<table>
<thead>
<tr>
<th>Region</th>
<th>Quotation Number</th>
<th>Envelope</th>
<th>Quantity</th>
<th>Date of Quotation</th>
<th>Date of Signing</th>
<th>Amount</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alhasana</td>
<td>EG-MOHP-83672-GO-RFQ</td>
<td>2018-11-14</td>
<td>60</td>
<td>98,300.00</td>
<td>2018-11-25</td>
<td>101,277.75</td>
<td>Pending</td>
</tr>
<tr>
<td>Sohag</td>
<td>EG-MOHP-83669-GO-RFQ</td>
<td>2018-11-14</td>
<td>60</td>
<td>98,200.00</td>
<td>2018-11-25</td>
<td>100,036.31</td>
<td>Completed</td>
</tr>
<tr>
<td>Saqlata</td>
<td>EG-MOHP-83687-GO-RFQ</td>
<td>2018-11-14</td>
<td>60</td>
<td>97,700.00</td>
<td>2018-11-25</td>
<td>99,682.66</td>
<td>Completed</td>
</tr>
<tr>
<td>Almunsha'a</td>
<td>EG-MOHP-83687-GO-RFQ</td>
<td>2018-11-14</td>
<td>60</td>
<td>97,700.00</td>
<td>2018-11-25</td>
<td>99,682.66</td>
<td>Completed</td>
</tr>
<tr>
<td>Ahansia</td>
<td>EG-MOHP-83687-GO-RFQ</td>
<td>2018-11-14</td>
<td>60</td>
<td>97,700.00</td>
<td>2018-11-25</td>
<td>99,682.66</td>
<td>Completed</td>
</tr>
<tr>
<td>Ahansia</td>
<td>EG-MOHP-83687-GO-RFQ</td>
<td>2018-11-14</td>
<td>60</td>
<td>97,700.00</td>
<td>2018-11-25</td>
<td>99,682.66</td>
<td>Completed</td>
</tr>
<tr>
<td>Ahansia</td>
<td>EG-MOHP-83687-GO-RFQ</td>
<td>2018-11-14</td>
<td>60</td>
<td>97,700.00</td>
<td>2018-11-25</td>
<td>99,682.66</td>
<td>Completed</td>
</tr>
<tr>
<td>Ahansia</td>
<td>EG-MOHP-83687-GO-RFQ</td>
<td>2018-11-14</td>
<td>60</td>
<td>97,700.00</td>
<td>2018-11-25</td>
<td>99,682.66</td>
<td>Completed</td>
</tr>
<tr>
<td>Ahansia</td>
<td>EG-MOHP-83687-GO-RFQ</td>
<td>2018-11-14</td>
<td>60</td>
<td>97,700.00</td>
<td>2018-11-25</td>
<td>99,682.66</td>
<td>Completed</td>
</tr>
<tr>
<td>Ahansia</td>
<td>EG-MOHP-83687-GO-RFQ</td>
<td>2018-11-14</td>
<td>60</td>
<td>97,700.00</td>
<td>2018-11-25</td>
<td>99,682.66</td>
<td>Completed</td>
</tr>
<tr>
<td>Ahansia</td>
<td>EG-MOHP-83687-GO-RFQ</td>
<td>2018-11-14</td>
<td>60</td>
<td>97,700.00</td>
<td>2018-11-25</td>
<td>99,682.66</td>
<td>Completed</td>
</tr>
<tr>
<td>Ahansia</td>
<td>EG-MOHP-83687-GO-RFQ</td>
<td>2018-11-14</td>
<td>60</td>
<td>97,700.00</td>
<td>2018-11-25</td>
<td>99,682.66</td>
<td>Completed</td>
</tr>
<tr>
<td>Ahansia</td>
<td>EG-MOHP-83687-GO-RFQ</td>
<td>2018-11-14</td>
<td>60</td>
<td>97,700.00</td>
<td>2018-11-25</td>
<td>99,682.66</td>
<td>Completed</td>
</tr>
</tbody>
</table>
### Table: Combination Treatment MEDICINES

<table>
<thead>
<tr>
<th>District</th>
<th>Code</th>
<th>Item Description</th>
<th>Price</th>
<th>Quantity</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aljanayn</td>
<td>EG-MOHP-88969-GO-RFQ</td>
<td>Daclatasvir 400mg+</td>
<td>98,600.00</td>
<td>1</td>
<td>98,600.00</td>
</tr>
<tr>
<td>Safaga</td>
<td>EG-MOHP-83804-GO-RFQ</td>
<td>Daclatasvir 400mg+</td>
<td>98,500.00</td>
<td>1</td>
<td>98,500.00</td>
</tr>
<tr>
<td>Ras Sofosbuvir</td>
<td>EG-MOHP-83801-GO-RFQ</td>
<td>Daclatasvir 400mg+</td>
<td>98,200.00</td>
<td>1</td>
<td>98,200.00</td>
</tr>
<tr>
<td>Alqasasin</td>
<td>EG-MOHP-83800-GO-RFQ</td>
<td>Daclatasvir 400mg+</td>
<td>97,900.00</td>
<td>1</td>
<td>97,900.00</td>
</tr>
<tr>
<td>Hurghada</td>
<td>EG-MOHP-83794-GO-RFQ</td>
<td>Daclatasvir 400mg+</td>
<td>97,800.00</td>
<td>1</td>
<td>97,800.00</td>
</tr>
<tr>
<td>El Sweir</td>
<td>EG-MOHP-83779-GO-RFQ</td>
<td>Daclatasvir 400mg+</td>
<td>99,100.00</td>
<td>1</td>
<td>99,100.00</td>
</tr>
<tr>
<td>Safaga</td>
<td>EG-MOHP-83775-GO-RFQ</td>
<td>Daclatasvir 400mg+</td>
<td>101,722.68</td>
<td>1</td>
<td>101,722.68</td>
</tr>
</tbody>
</table>

**Total:** 101,722.68
<table>
<thead>
<tr>
<th>Purchasing Unit</th>
<th>Envelope Stage</th>
<th>Request Submitted</th>
<th>Request Signed</th>
<th>Pending Implementation</th>
<th>Implement Schedule</th>
<th>IBRD Stages</th>
<th>Envelope Cost</th>
<th>88950 Stages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eleiny</td>
<td>Single</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
</tr>
<tr>
<td>Rashid</td>
<td>Single</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
</tr>
<tr>
<td>Koum</td>
<td>Single</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
</tr>
<tr>
<td>Samalut</td>
<td>Single</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
</tr>
<tr>
<td>EG-MOHP-92465</td>
<td>Single</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
</tr>
<tr>
<td>EG-MOHP-92461</td>
<td>Single</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
</tr>
<tr>
<td>EG-MOHP-92459</td>
<td>Single</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
</tr>
<tr>
<td>EG-MOHP-92458</td>
<td>Single</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
<td>88950</td>
</tr>
</tbody>
</table>

**Notes:**
- All stages are marked as completed in the IBRD stages column.
- Envelope cost is listed as 88950 for all units.
- Pending implementation times are not specified but can be inferred from the IBRD stages column.
<table>
<thead>
<tr>
<th>Location</th>
<th>Price</th>
<th>Date</th>
<th>Payment Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matrouh</td>
<td>88,950</td>
<td>2018-12-29</td>
<td>Single Envelope Stage 1</td>
</tr>
<tr>
<td>El Ghamr</td>
<td>98,200</td>
<td>2018-12-29</td>
<td>Single Envelope Stage 1</td>
</tr>
<tr>
<td>Middle Matrouh</td>
<td>98,400</td>
<td>2018-12-29</td>
<td>Single Envelope Stage 1</td>
</tr>
<tr>
<td>Matrouh</td>
<td>98,400</td>
<td>2018-12-29</td>
<td>Single Envelope Stage 1</td>
</tr>
<tr>
<td>Matrouh</td>
<td>98,900</td>
<td>2018-12-29</td>
<td>Single Envelope Stage 1</td>
</tr>
<tr>
<td>Matrouh</td>
<td>98,700</td>
<td>2019-01-08</td>
<td>Single Envelope Stage 1</td>
</tr>
<tr>
<td>Matrouh</td>
<td>105,303.59</td>
<td>2019-03-07</td>
<td>Single Envelope Stage 1</td>
</tr>
</tbody>
</table>

Note: The requested products are Sofosbuvir and Daclatasvir for the treatment of hepatitis C virus.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Combination</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sofosbuvir</td>
<td>400mg+</td>
<td>60mg</td>
</tr>
<tr>
<td>Daclatasvir</td>
<td>400mg+</td>
<td>60mg</td>
</tr>
<tr>
<td>Sofosbuvir</td>
<td>400mg+</td>
<td>60mg</td>
</tr>
<tr>
<td>Daclatasvir</td>
<td>400mg+</td>
<td>60mg</td>
</tr>
<tr>
<td>Sofosbuvir</td>
<td>400mg+</td>
<td>60mg</td>
</tr>
<tr>
<td>Daclatasvir</td>
<td>400mg+</td>
<td>60mg</td>
</tr>
</tbody>
</table>

*Note: The table above represents the combination of Sofosbuvir and Daclatasvir used in the treatment of the virus.*

*Source: EG-MOHP-92556-GO-RFQ, EG-MOHP-92538-GO-RFQ, EG-MOHP-92537-GO-RFQ*

*El Shoubra Nasr Damanhour Sedfa*
<table>
<thead>
<tr>
<th>ID</th>
<th>Purchasing</th>
<th>Name</th>
<th>Number</th>
<th>Unit</th>
<th>Cost (EGP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EG-MOHP-92575-GO-RFQ</td>
<td>Purchasing</td>
<td>Nassar</td>
<td>60</td>
<td></td>
<td>97,800.00</td>
</tr>
<tr>
<td>EG-MOHP-92584-GO-RFQ</td>
<td>Purchasing</td>
<td>Fared</td>
<td>12</td>
<td></td>
<td>98,100.00</td>
</tr>
<tr>
<td>EG-MOHP-92585-GO-RFQ</td>
<td>Purchasing</td>
<td>Shokr</td>
<td>12</td>
<td></td>
<td>98,200.00</td>
</tr>
<tr>
<td>EG-MOHP-92590-GO-RFQ</td>
<td>Purchasing</td>
<td>Shohada</td>
<td>12</td>
<td></td>
<td>98,700.00</td>
</tr>
<tr>
<td>EG-MOHP-92591-GO-RFQ</td>
<td>Purchasing</td>
<td>Kafr Qalyoub</td>
<td>12</td>
<td></td>
<td>97,250.00</td>
</tr>
<tr>
<td>EG-MOHP-92592-GO-RFQ</td>
<td>Purchasing</td>
<td>Ashmoun</td>
<td>12</td>
<td></td>
<td>98,100.00</td>
</tr>
</tbody>
</table>

**Notes:**
- Daclatasvir is used for a combination treatment.
- Sofosbuvir is used for a combination treatment.
- All treatments are under the national insurance program.
<table>
<thead>
<tr>
<th>ID</th>
<th>Quotations Request Date</th>
<th>Request Date</th>
<th>Original Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>EG-MOHP-99026-GO-RFQ</td>
<td>2019-02-23</td>
<td>2019-02-23</td>
<td>97,500.00</td>
</tr>
<tr>
<td>EG-MOHP-99022-GO-RFQ</td>
<td>2019-02-23</td>
<td>2019-02-23</td>
<td>97,300.00</td>
</tr>
<tr>
<td>EG-MOHP-99021-GO-RFQ</td>
<td>2019-02-23</td>
<td>2019-02-23</td>
<td>97,200.00</td>
</tr>
<tr>
<td>EG-MOHP-99020-GO-RFQ</td>
<td>2019-02-23</td>
<td>2019-02-23</td>
<td>99,000.00</td>
</tr>
<tr>
<td>EG-MOHP-99010-GO-RFQ</td>
<td>2019-03-02</td>
<td>2019-03-02</td>
<td>104,067.39</td>
</tr>
</tbody>
</table>

**Notes:**
- All amounts are in Egyptian Pounds (EGP).
- Original Amounts are used for programming and purchasing districts.
to
Daclatasvir
Sofosbuvir
Egyptian
drugs
are
currently
weeks
Daclatasvir
Sofosbuvir
national
to
Sofosbuvir
national
to
weeks
national
to
Sofosbuvir
national
to
Sofosbuvir
currently
to
national
to
EG-MOHP-99280-GO-RFQ
EG-MOHP-99275-GO-RFQ
EG-MOHP-99039-GO-RFQ
Purchasing
Purchasing
Purchasing
Purchasing
kwam
ebshuy
shubra
qaha
Elbadari
combination
treatment
400mg+
district.
virus
drugs
of
for
400mg+
C
program/
88950
Level
Strengthen
Healthcare
Secondary
Post
Quotations
Limited
One
Stage
-2019-02-
98,300.00
23
2019-05-
104,471.15
23
2019-02-
105,576.92
23
2019-02-
Signed
2019-02-
2019-02-
<table>
<thead>
<tr>
<th>Governorate</th>
<th>Code</th>
<th>Current</th>
<th>RFQ</th>
<th>Purchasing</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cairo</td>
<td>EG-MOHP-115215-GO-</td>
<td>98,300.00</td>
<td>2019-05-24</td>
<td>98,300.00</td>
<td>60</td>
</tr>
<tr>
<td>Giza</td>
<td>EG-MOHP-115214-GO-</td>
<td>98,400.00</td>
<td>2019-05-25</td>
<td>98,400.00</td>
<td>60</td>
</tr>
<tr>
<td>Elminya</td>
<td>EG-MOHP-115213-GO-</td>
<td>98,500.00</td>
<td>2019-05-26</td>
<td>98,500.00</td>
<td>60</td>
</tr>
<tr>
<td>Hurghada</td>
<td>EG-MOHP-115212-GO-</td>
<td>98,600.00</td>
<td>2019-05-27</td>
<td>98,600.00</td>
<td>60</td>
</tr>
<tr>
<td>Minya</td>
<td>EG-MOHP-115211-GO-</td>
<td>98,700.00</td>
<td>2019-05-28</td>
<td>98,700.00</td>
<td>60</td>
</tr>
<tr>
<td>Monufiya</td>
<td>EG-MOHP-115210-GO-</td>
<td>98,800.00</td>
<td>2019-05-29</td>
<td>98,800.00</td>
<td>60</td>
</tr>
<tr>
<td>Qena</td>
<td>EG-MOHP-115209-GO-</td>
<td>98,900.00</td>
<td>2019-05-30</td>
<td>98,900.00</td>
<td>60</td>
</tr>
</tbody>
</table>

* Daclatasvir and Sofosbuvir are currently being used for the treatment of Hepatitis C virus in Egypt. The usage is through a combination of 400 mg of Daclatasvir and 12 mg of Sofosbuvir per day for 12 weeks.*
<table>
<thead>
<tr>
<th>ID</th>
<th>Scheme</th>
<th>Stage 1</th>
<th>Stage 2</th>
<th>Stage 3</th>
<th>Stage 4</th>
<th>Stage 5</th>
<th>Stage 6</th>
<th>Stage 7</th>
<th>Stage 8</th>
<th>Stage 9</th>
<th>Stage 10</th>
<th>Stage 11</th>
<th>Stage 12</th>
<th>Stage 13</th>
</tr>
</thead>
<tbody>
<tr>
<td>EG-MOHP-115370-GO-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-115366-GO-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-115361-GO-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-115353-GO-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-115175-GO-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-115345-GO-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-115330-GO-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**
- **Scheme:** Program details.
- **Stage 1-13:** Specific stages or milestones in the procurement process.

**Key:**
- **ID:** Unique identifier for each procurement.
- **Stage 1-13:** Stages of the procurement process, each with specific identifiers.

**Program Details:**
- **Envelopes:** Details of the procurement process.
- **Limiting Factors:** Factors affecting the procurement process.

**Prices:**
- **Signed:** Prices of the procurements.
- **98,500.00**
- **99,200.00**
- **98,500.00**
- **98,200.00**
- **98,700.00**
- **104,693.14**
- **106,650.60**
- **105,752.10**
- **105,463.29**
- **106,425.99**
<table>
<thead>
<tr>
<th>Country</th>
<th>Combination</th>
<th>Treatment</th>
<th>Monthly</th>
<th>Total Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Egypt</td>
<td>Daclatasvir + Sofosbuvir</td>
<td>through the RFQ</td>
<td>mg</td>
<td>for 12 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>12</td>
<td></td>
</tr>
</tbody>
</table>

**EG-MOHP-115460**

**EG-MOHP-115456**

**EG-MOHP-115447**

**EG-MOHP-038200**
<table>
<thead>
<tr>
<th>Country</th>
<th>Code</th>
<th>District</th>
<th>Quantity</th>
<th>Unit</th>
<th>Price</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Egypt</td>
<td>EGY</td>
<td>Gharb</td>
<td>12</td>
<td>week</td>
<td>88,950</td>
<td>1,064,411.09</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kom</td>
<td>60</td>
<td>week</td>
<td>88,950</td>
<td>5,280,000.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ahansia</td>
<td>60</td>
<td>week</td>
<td>88,950</td>
<td>5,280,000.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quesna</td>
<td>60</td>
<td>week</td>
<td>88,950</td>
<td>5,280,000.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Karna</td>
<td>60</td>
<td>week</td>
<td>88,950</td>
<td>5,280,000.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kom</td>
<td>60</td>
<td>week</td>
<td>88,950</td>
<td>5,280,000.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ahansia</td>
<td>60</td>
<td>week</td>
<td>88,950</td>
<td>5,280,000.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quesna</td>
<td>60</td>
<td>week</td>
<td>88,950</td>
<td>5,280,000.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Karna</td>
<td>60</td>
<td>week</td>
<td>88,950</td>
<td>5,280,000.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kom</td>
<td>60</td>
<td>week</td>
<td>88,950</td>
<td>5,280,000.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ahansia</td>
<td>60</td>
<td>week</td>
<td>88,950</td>
<td>5,280,000.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quesna</td>
<td>60</td>
<td>week</td>
<td>88,950</td>
<td>5,280,000.00</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Karna</td>
<td>60</td>
<td>week</td>
<td>88,950</td>
<td>5,280,000.00</td>
</tr>
</tbody>
</table>

**Notes:**
- The total cost is calculated by multiplying the quantity by the price per unit.
- The total cost is rounded to the nearest whole number.
- The currency used is the Egyptian Pound (EGP).
- The quantities are measured in weeks.
medicines

400mg+

for

400mg+

medicines

Purchasing

treatment

for

the

combination

C

Egyptian

RFQ

district.

combination

medicines

Egyptian

medicines

RFQ

EG-MOHP-115762-GO-

EG-MOHP-115774-GO-

MOHP-115211

EG-MOHP-115729-GO-

EG-MOHP-115735-GO-

EG-MOHP-115778-GO-

EG-MOHP-115727-GO-

medicines

medicines

/12
/12
weeks

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasvir

Daclatasv
<table>
<thead>
<tr>
<th>Envelope</th>
<th>Level</th>
<th>Stage</th>
<th>Request</th>
<th>Quotations</th>
<th>Implement</th>
<th>Under</th>
<th>Pending</th>
<th>Post</th>
<th>Healthcare</th>
<th>Strengthen</th>
<th>Post</th>
<th>Healthcare</th>
<th>Strengthen</th>
<th>Post</th>
<th>Healthcare</th>
<th>Strengthen</th>
<th>Post</th>
<th>Healthcare</th>
<th>Strengthen</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Product Code</td>
<td>Unit</td>
<td>Quantity</td>
<td>Price</td>
<td>Total</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------</td>
<td>----------</td>
<td>--------</td>
<td>--------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-115777-GO-</td>
<td>400mg + Daclatasvir</td>
<td>12 weeks</td>
<td>98,200.00</td>
<td>1,178,400.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-115724-GO-</td>
<td>12 weeks</td>
<td>12 weeks</td>
<td>99,200.00</td>
<td>1,189,600.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-115788-GO-</td>
<td>12 weeks</td>
<td>12 weeks</td>
<td>104,929.90</td>
<td>1,259,159.80</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EG-MOHP-115794-GO-</td>
<td>12 weeks</td>
<td>12 weeks</td>
<td>106,199.39</td>
<td>1,274,399.18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Note: The prices are in Egyptian pounds.*
<table>
<thead>
<tr>
<th>Envelope</th>
<th>Stage</th>
<th>Date</th>
<th>Institute</th>
<th>Type</th>
<th>Grade</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>EG-MOHP-94062-GO-RFQ</td>
<td>-</td>
<td>2019-01-30</td>
<td>University Hospital</td>
<td>Qalyubia</td>
<td>Governorate</td>
<td>Management</td>
</tr>
<tr>
<td>EG-MOHP-123283-GO-RFQ</td>
<td>-</td>
<td>2019-01-30</td>
<td>Qalyubia</td>
<td>Governorate</td>
<td>Management</td>
<td>Equipment</td>
</tr>
<tr>
<td>EG-MOHP-123276-GO-RFQ</td>
<td>-</td>
<td>2019-01-30</td>
<td>Qalyubia</td>
<td>Governorate</td>
<td>Management</td>
<td>Equipment</td>
</tr>
<tr>
<td>EG-MOHP-123278-GO-RFQ</td>
<td>-</td>
<td>2019-01-30</td>
<td>Qalyubia</td>
<td>Governorate</td>
<td>Management</td>
<td>Equipment</td>
</tr>
<tr>
<td>EG-MOHP-123287-GO-RFQ</td>
<td>-</td>
<td>2019-01-30</td>
<td>Qalyubia</td>
<td>Governorate</td>
<td>Management</td>
<td>Equipment</td>
</tr>
<tr>
<td>EG-MOHP-123294-GO-RFQ</td>
<td>-</td>
<td>2019-01-30</td>
<td>Qalyubia</td>
<td>Governorate</td>
<td>Management</td>
<td>Equipment</td>
</tr>
</tbody>
</table>

This combination tablet contains sofosbuvir 400 mg and velpatasvir. This tablet contains sofosbuvir 100 mg and velpatasvir. Each treatment unit contains 400 mg sofosbuvir and 100 mg velpatasvir.

In the Tanta Medical Institute and the Sharm Hospital for Fever Centers, each of the following family and post unit was purchased:

<table>
<thead>
<tr>
<th>IBRD</th>
<th>Stage</th>
<th>Grade</th>
<th>Date</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>13,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>15,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>27,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>22,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>19,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>19,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>98,300.00</td>
</tr>
</tbody>
</table>

- 2019-02-08: Single Pending
- 2019-04-29: Single Pending
- 2019-09-09: Single Pending

For the Qena Family Health, Asyut Family Health, and Aswan Family Health, each of the following community facilities and post unit was purchased:

<table>
<thead>
<tr>
<th>IBRD</th>
<th>Stage</th>
<th>Grade</th>
<th>Date</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>13,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>15,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>27,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>22,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>19,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>19,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>98,300.00</td>
</tr>
</tbody>
</table>

- 2019-01-30: One Canceled
- 2019-02-08: Single Pending
- 2019-04-29: Single Pending
- 2019-09-09: Single Pending

For the Shaben Post in Asyut, the following post unit was purchased:

<table>
<thead>
<tr>
<th>IBRD</th>
<th>Stage</th>
<th>Grade</th>
<th>Date</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>13,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>15,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>27,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>22,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>19,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>19,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>98,300.00</td>
</tr>
</tbody>
</table>

- 2019-01-30: One Canceled
- 2019-02-08: Single Pending
- 2019-04-29: Single Pending
- 2019-09-09: Single Pending

For the IBRD Limited, the following post unit was purchased:

<table>
<thead>
<tr>
<th>IBRD</th>
<th>Stage</th>
<th>Grade</th>
<th>Date</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>13,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>15,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>27,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>22,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>19,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>19,000.00</td>
</tr>
<tr>
<td>88950</td>
<td>-</td>
<td>Fixed</td>
<td>2019-01-30</td>
<td>98,300.00</td>
</tr>
</tbody>
</table>

- 2019-01-30: One Canceled
- 2019-02-08: Single Pending
- 2019-04-29: Single Pending
- 2019-09-09: Single Pending

Quotations Request for Limited Single Stage Envelope was submitted on 2019-01-30 with a quantity of 13,000.00.
<table>
<thead>
<tr>
<th>No.</th>
<th>Contract Type</th>
<th>Component Description</th>
<th>Selection Consultant Method</th>
<th>Estimated Amount (US$)</th>
<th>Actual Amount (US$)</th>
<th>Amount Canceled (US$)</th>
<th>Terms of Reference</th>
<th>Type of Request</th>
<th>Interest Amount (US$)</th>
<th>Quantity of Items</th>
<th>Signing Date</th>
<th>Notification Date</th>
<th>Planned Completion Date</th>
<th>Actual Completion Date</th>
<th>Pending Implementation</th>
<th>Evaluation Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Fixed</td>
<td>Health, Strengthen Community Capacity</td>
<td>Limited Approach - National Market</td>
<td>1,500,000.00</td>
<td>29,000.00</td>
<td>0.00</td>
<td>Draft</td>
<td>Notice</td>
<td>0.00</td>
<td>30</td>
<td>2019-09-23</td>
<td>2018-12-23</td>
<td>2019-08-15</td>
<td>2019-07-15</td>
<td>2019-07-15</td>
<td>2019-08-15</td>
</tr>
<tr>
<td>2</td>
<td>Fixed</td>
<td>Specific Activities</td>
<td>Least Quotations Method</td>
<td>16,150.00</td>
<td>12,000.00</td>
<td>4,150.00</td>
<td>Draft</td>
<td>Notice</td>
<td>30,000.00</td>
<td>30</td>
<td>2019-08-20</td>
<td>2019-08-20</td>
<td>2019-07-20</td>
<td>2019-06-20</td>
<td>2019-06-20</td>
<td>2019-07-20</td>
</tr>
<tr>
<td>3</td>
<td>Fixed</td>
<td>Building Institutional Activities</td>
<td>Selection Consultant - Individual</td>
<td>299,000.00</td>
<td>18,000.00</td>
<td>181,000.00</td>
<td>Draft</td>
<td>Notice</td>
<td>0.00</td>
<td>20</td>
<td>2019-09-23</td>
<td>2019-09-23</td>
<td>2019-07-23</td>
<td>2019-05-23</td>
<td>2019-05-23</td>
<td>2019-07-23</td>
</tr>
<tr>
<td>5</td>
<td>Fixed</td>
<td>Building Institutional Activities</td>
<td>Selection Consultant - Individual</td>
<td>1,500,000.00</td>
<td>0.00</td>
<td>1,500,000.00</td>
<td>Draft</td>
<td>Notice</td>
<td>0.00</td>
<td>30</td>
<td>2019-09-23</td>
<td>2019-09-23</td>
<td>2019-07-23</td>
<td>2019-04-15</td>
<td>2019-04-15</td>
<td>2019-07-23</td>
</tr>
</tbody>
</table>